Fewer than one in four depressed patients are in remission after a minimum of six weeks’ treatment with antidepressants, a UK primary care cross-sectional study has found. The data were collected during the initial stage of the CoBalT study, a randomised controlled trial of CBT augmentation for treatment-resistant depression.1 A total of 2,129 participants were recruited from 73 general practices. Eligible patients were those aged 18-75 who had been prescribed an adequate dose of antidepressant medication for at least six weeks.